Hememics Biotechnologies

Hememics Biotechnologies, Inc. is a Maryland-based biotechnology firm that develops handheld, multiplexed biosensor platforms designed to provide lab-quality diagnostic results at the point of need. Its core technology, the HemChip platform, features a portable reader and a single-use biochip with 32 programmable sensors capable of simultaneously detecting molecular, antigen, and antibody targets within five minutes. The company also utilizes its patented ESAP (Electrostatic Sensing for Analyte Profiling) platform, which uses graphene-based electronics to enable rapid, label-free protein and antibody validation. By integrating patented bio-preservatives with graphene-based sensors, Hememics aims to make complex biomolecular analysis faster and more accessible for diverse applications ranging from research laboratories to clinical and field environments.

This technology addresses significant challenges in research integrity and diagnostics, such as the reliability of research reagents and the need for rapid pathogen identification. By delivering definitive binding results in under one hour for research or within five minutes for diagnostic testing, Hememics provides tools for quality control and field-ready decision-making. The company has successfully demonstrated the utility of its ESAP platform in commercial trial workflows and is supported by financing from investors including TEDCO. Their work centers on simplifying laboratory workflows and extending the utility of biological samples through innovation in sensor technology and preservation methods.